Enhabit (EHAB) Q2 2025 Earnings
Reported Aug 6, 2025 at 4:26 PM ET · SEC Source
Q2 25 EPS
$0.13
BEAT +30.78%
Est. $0.10
Q2 25 Revenue
$266.1M
BEAT +1.03%
Est. $263.4M
vs S&P Since Q2 25
+84.9%
BEATING MARKET
EHAB +103.8% vs S&P +18.9%
Market Reaction
Did EHAB Beat Earnings? Q2 2025 Results
Enhabit delivered a convincing second-quarter beat on both the top and bottom lines, with earnings per share of $0.13 clearing the $0.10 consensus estimate by 30.78% and net service revenue of $266.10 million edging past expectations by 1.03% while g… Read more Enhabit delivered a convincing second-quarter beat on both the top and bottom lines, with earnings per share of $0.13 clearing the $0.10 consensus estimate by 30.78% and net service revenue of $266.10 million edging past expectations by 1.03% while growing 2.1% year over year. The clearest engine behind the outperformance was hospice, where net service revenue surged 19.4% year over year to $60.20 million and segment adjusted EBITDA jumped 53.8% to $14.00 million as average daily census posted its sixth consecutive quarter of sequential growth. Net income swung to $5.20 million from a loss in the year-ago period, while adjusted EBITDA rose 6.7% to $26.90 million with margin expanding to 10.1%. The quarter also carried notable leadership news, as the company announced a CEO transition plan with Barb Jacobsmeyer set to remain in her role until a successor is named. Encouraged by hospice momentum and sequential stabilization in home health, Enhabit raised its full-year 2025 adjusted EBITDA guidance to $104 million to $108 million and lifted adjusted EPS guidance to $0.47 to $0.55.
Key Takeaways
- • Hospice ADC increased 12.3% year over year, sixth consecutive quarter of sequential growth
- • Home health non-Medicare admissions increased 5.2% year over year
- • Successful renegotiation of a national payer agreement with low double-digit % rate increase
- • Home health Medicare ADC rate of decline more than halved to 3.4% vs. 14.1% decline in prior year period
- • Hospice revenue per patient day improved 6.3% year over year
- • Home health cost per patient day remained flat year over year
- • Consolidated Adjusted EBITDA grew 6.7% year over year to $26.9M
- • Home office G&A expenses as percentage of revenue improved to 9.9% from 10.8%
EHAB YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
EHAB Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our second quarter results reflect strong execution of our strategic 2025 priorities, with sequential and year-over-year growth in revenue and Adjusted EBITDA. Home health continued to benefit from our payer contract initiatives as admissions grew 1.3% year over year and saw further stabilization in Medicare Fee-for-Service census. Hospice delivered its sixth consecutive quarter of growth with average daily census rising 12.3% year over year. We also strengthened our balance sheet by reducing bank debt and increasing liquidity. With this momentum, we're well positioned for success in the second half of 2025.”
— Barb Jacobsmeyer, Q2 2025 Earnings Press Release
EHAB Earnings Trends
EHAB vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
EHAB EPS Trend
Earnings per share: estimate vs actual
EHAB Revenue Trend
Quarterly revenue: estimate vs actual
EHAB Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 MISS FY | $0.15 | $0.14 | -8.44% | $270.4M | -0.06% |
| FY Full Year | $0.56 | $0.53 | -5.88% | $1.06B | -0.01% |
| Q3 25 BEAT | $0.12 | $0.17 | +42.38% | $263.6M | -1.33% |
| Q2 25 BEAT | $0.10 | $0.13 | +30.78% | $266.1M | +1.03% |
| Q1 25 BEAT | $0.06 | $0.10 | +60.26% | $259.9M | -2.33% |